Recordati Sets 3-Year Goals Driven By Organic Growth & M&A

Recordati Sets 3-Year Goals Driven By Organic Growth & M&A

By Karen Roman Recordati said it established its three-year financial targets for 2025-2027, with expected revenue of €3.0 to €3.2 billion for 2027 and EBITDA of €1.14 to €1.225 billion. The company’s strategy is driven by organic growth, its leadership,...

Araris Biotech Partners with Johnson & Johnson to Develop Cancer Therapies

Araris Biotech Partners with Johnson & Johnson to Develop Cancer Therapies

By Daniella Parra Araris Biotech AG  joined a research agreement with Johnson & Johnson’s Janssen Biotech to advance the development of next-generation antibody-drug conjugates (ADCs), they said. The partnership will leverage Araris’ proprietary AraLinQ technology, a one-step, enzymatic conjugation platform...

Input your search keywords and press Enter.